28 Oct, 2021
The Asia Biopharma Industry Innovation Summit 2021, hosted by Taas Labs, kicked off in Shanghai on October 28. Dr. Joe ZHOU, Founder & President of Genor Biopharma, delivered an opening speech with the theme of "Current Status and Trends of Antibody Drug Development: BsAb." He shared his views on the changes in the biopharmaceutical industry, the current status of China's drug regulatory environment, and the opportunities and challenges in the development of biologic drugs. He also introduced the progress of Genor Biopharma bispecific/multi-specific antibodies.
20 Oct, 2021
Mr. LIANG Qibin, the former President of CMAB Biopharma, will join Genor Biopharma as Chief Technology Officer. With Mr. LIANG Qibin joining the company, it will further strengthen the innovation ability of core technologies and achieve efficient innovation in technology, research and development, processes, management and other areas.
27 Sep, 2021
2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists were officially released during China BioMed Innovation and Investment Conference, Genor Biopharma was included in the Chinese Antibody Drug Companies Innovation TOP 30.
20 Sep, 2021
Dr. SHI Yuankai, M.D. Professor of Medical Oncology Department of Medical Oncology Deputy Director of National Cancer Center, Vice President of Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, orally presented the clinical data at ESMO (European Society for Medical Oncology) Congress 2021. The clinical trial was designed to evaluate the efficacy and safety of Geptanolimab monotherapy in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).
10 Sep, 2021
Genor Biopharma (Stock code: 6998.HK) announced today that the latest clinical data on Geptanolimab (GB226) would be presented at ESMO (European Society for Medical Oncology) Congress 2021.